How the Commission of Brussels and EU states will move on the Covid vaccine

How the Commission of Brussels and EU states will move on the Covid vaccine

Covid-19 vaccine: the announcement of the EU Commission, the choices of France, Germany, Italy and the Netherlands, and relations with pharmaceutical companies

2.4 billion. This is what the EU Commission puts on the plate to allow the various Member States to have a vaccine against Covid-19 within the next 12-18 months. The money, taken from the emergency fund, will serve to finance part of the initial costs incurred by the producers.

To move are also in various countries of the Old Continent. Italy, together with Holland, France and Germany, entered into an agreement with AstraZeneca last week, while Paris and Berlin are also moving in solitude to secure the antitodus against the coronavirus. Let's go step by step.

THE EU AGREEMENT FOR VACCINES

Let's start with the news coming from Brussels. The European Commission has today decided to sign agreements with individual manufacturers of the Covid-19 vaccines on behalf of the Member States: in exchange for good initial economic support of € 2.4 billion (which is valid as an advance payment on the supply), companies are committed to providing a vaccine within a maximum of 18 months.

USED ​​EMERGENCY FUND

The money will be taken significantly from the 2.7 billion euro EU emergency support tool.

HOW DO YOU CHOOSE WHO FINANCE?

Not all producers will be financed , but only those who will show solidity in the scientific approach and technology used and good large-scale delivery capacity in a short time, says the European executive. The selection criteria also include cost, risk sharing and responsibility.

THE WORDS OF VON DER LEYEN

“We are working on a global summit on June 27th. We will explore with our international partners the possibility that a significant number of countries will agree to pool resources to jointly book future vaccines from pharmaceutical companies, while making advance reservations for low-middle income countries, " said President Ursula. von der Leyen, in a video message.

“High-income countries would act as an international and inclusive group of buyers, thereby accelerating the development of safe and effective vaccines and helping to maximize access to the world for those who need it. When it comes to fighting a global pandemic, there is no place for those who say 'I before', "specified the President of the EU Commission.

THE STRATEGY OF ITALY, HOLLAND, FRANCE AND GERMANY

How the Brussels strategy is reconciled with the choices of Italy, France, Holland and Germany. The 4 countries have aimed at a single contract with the British multinational AstraZeneca for the supply of 400 million doses of Covid-19 vaccine, to be destined for the whole European population.

AstraZeneca will produce (also in the Italian Irbm plant) the vaccine developed by the Jenner Institute of the University of Oxford, in collaboration with the Oxford Vaccine Group and the Irbm of Pomezia, and currently in the advanced testing phase. It is currently the most promising vaccine and AstraZeneca aims to put it on the market by the end of 2020.

The 4 countries could also enter into a contract, writes La Stampa , with the American Johnson & Johnson, who has another promising vaccine candidate.

FRANCE MOVES WITH SANOFI

France also seems to want to try the home route and allocate 200 million euros to Sanofi, to increase efforts and production on a national level. The initiative comes, writes Repubblica , after rumors that the US would have had priority in the distribution of the future vaccine made by the European pharmaceutical giant.

Meanwhile, Sanofi has promised to invest 610 million for a new factory on the outskirts of Lyon.

GERMANY READY TO ACQUIRE CUREVAC

Germany also relies on home horses. The Merkel government is even ready to shop and buy 23% of Curevac, the Tübingen company engaged in the development of the vaccine in collaboration with the Biontech of Mainz. Berlin thus highlights the territory after rumors of a possible purchase by the US of Trump (rumors that led to Chancellor Angela Merkel to put all health and biotech companies under government protection from any purchases over 10% ).

EU: YOU MUST MOVE TOGETHER

The initiatives in solitude, however, do not please the EU. And just the European Commissioner for Health, Stella Kyriakides, in recent days has invited States to move in agreement with Brussels: "This will avoid competition between us and offer vaccine manufacturers a simplified negotiation process," said Kyriakides .


This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/innovazione/come-si-muoveranno-commissione-di-bruxelles-e-stati-ue-sul-vaccino-anti-covid/?utm_source=rss&utm_medium=rss&utm_campaign=come-si-muoveranno-commissione-di-bruxelles-e-stati-ue-sul-vaccino-anti-covid on Wed, 17 Jun 2020 14:25:41 +0000.